Stockscreener 앱 받기
20.28
1.41%
-0.29
전일 마감가:
$20.57
열려 있는:
$20.4
하루 거래량:
210.98K
Relative Volume:
0.56
시가총액:
$524.04M
수익:
순이익/손실:
$-184.46M
주가수익비율:
-0.1421
EPS:
-142.7277
순현금흐름:
$-24.11M
1주 성능:
-1.55%
1개월 성능:
-39.28%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$20.02
$21.65
1주일 범위
$18.29
$21.97
52주 변동 폭
$13.43
$42.14
Faeth Therapeutics Inc Stock (FTH) Company Profile
명칭
Faeth Therapeutics Inc
전화
(240) 243-8000
주소
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
20.28 | 524.04M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
536.48 | 135.98B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
821.59 | 84.59B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.19 | 79.12B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
876.45 | 55.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.50 | 43.27B | 5.76B | 514.49M | 1.10B | 4.4813 |
Faeth Therapeutics Inc Stock (FTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-16 | 개시 | William Blair | Outperform |
| 2026-09-16 | 개시 | Guggenheim | Buy |
| 2026-09-09 | 개시 | TD Cowen | Buy |
| 2026-08-21 | 개시 | Needham | Buy |
| 2026-07-31 | 개시 | Raymond James | Outperform |
| 2026-07-28 | 개시 | Oppenheimer | Outperform |
| 2026-07-20 | 개시 | Citizens | Mkt Outperform |
| 2026-06-26 | 개시 | Robert W. Baird | Outperform |
| 2026-06-22 | 개시 | H.C. Wainwright | Buy |
| 2026-06-11 | 개시 | BTIG Research | Buy |
| 2026-05-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-05-22 | 개시 | Citigroup | Buy |
| 2026-04-20 | 개시 | Leerink Partners | Outperform |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-06-29 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2021-03-01 | 개시 | Citigroup | Buy |
| 2021-03-01 | 개시 | Oppenheimer | Outperform |
| 2021-03-01 | 개시 | Piper Sandler | Overweight |
모두보기
Faeth Therapeutics Inc 주식(FTH)의 최신 뉴스
Faeth Therapeutics, Inc.Common Stock (Nasdaq:FTH) Stock Quote - FinancialContent
Faeth Therapeutics Director Karen H. Vousden Granted 25,000 Stock Options - Kalkine Media
Faeth Therapeutics (FTH) awards 25,000 stock options to director - Stock Titan
Faeth Therapeutics at Cantor Fitzgerald conference: oral PI3K push By Investing.com - Investing.com Canada
A booming business on Wall Street would love more biotechs to quietly die - BioPharma Dive
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
FTH Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com India
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com Canada
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com UK
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - BioSpace
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - Yahoo Finance
About 80% of endometrial tumors have a pathway alteration. Faeth will discuss PIKTOR. - Stock Titan
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - Business Wire
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Australia
Faeth Therapeutics stock hits 52-week high at 40.89 USD - investing.com
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Canada
Bullish Faeth Therapeutics Insiders Rewarded As Their Investment Rises To US$1.94m - simplywall.st
Insiders of Faeth Therapeutics Getting Good Value On Their US$1.19m Investment - Moomoo
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Eastern Progress
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Yahoo Finance Singapore
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Faeth Therapeutics (FTH) Grants Stock Options to New Hires Amid Unprofitable Growth Phase - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Capital expenditures of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know - Yahoo Finance
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - sahmcapital.com
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - Yahoo Finance
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - Business Wire
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - kalkine.ca
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - BioSpace
Faeth Therapeutics Inc (FTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Faeth Therapeutics Inc 주식 (FTH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer |
Jul 01 '26 |
Buy |
23.50 |
5,000 |
117,492 |
46,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 30 '26 |
Buy |
24.25 |
7,803 |
189,240 |
41,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 29 '26 |
Buy |
23.34 |
831 |
19,396 |
33,885 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 26 '26 |
Buy |
24.95 |
6,250 |
155,908 |
33,054 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 24 '26 |
Buy |
26.13 |
9,391 |
245,360 |
26,804 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 23 '26 |
Buy |
24.36 |
9,230 |
224,806 |
17,413 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Buy |
19.76 |
2,806 |
55,447 |
764,234 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Option Exercise |
1.16 |
53,465 |
62,019 |
817,699 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 22 '26 |
Buy |
22.13 |
8,183 |
181,115 |
8,183 |
| Cambrian BioPharma Inc | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
0.85%
3.40%
자본화:
|
볼륨(24시간):